A

References

Barrett, F. S., M. K. Doss, N. D. Sepeda, J. J. Pekar, and R. R. Griffiths. 2020. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports 10(1):2214. https://doi.org/10.1038/s41598-020-59282-y.

Bender, D., and D. J. Hellerstein. 2022. Assessing the risk–benefit profile of classical psychedelics: A clinical review of second-wave psychedelic research. Psychopharmacology 239:1907–1932. https://doi.org/10.1007/s00213-021-06049-6.

Bogenschutz, M. P., A. A. Forcehimes, J. A. Pommy, C. E. Wilcox, P. C. R. Barbosa, and R. J. Strassman. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29(3):289–299. https://doi.org/10.1177/0269881114565144.

Calderon, S. N., J. Hunt, and M. Klein. 2018. A regulatory perspective on the evaluation of hallucinogen drugs for human use. Neuropharmacology 142(November):135–142. https://doi.org/10.1016/j.neuropharm.2017.11.028.

Cameron, L. P., R. J. Tombari, J. Lu, A. J. Pell, Z. Q. Hurley, Y. Ehinger, M. V. Vargas, M. N. McCarroll, J. C. Taylor, D. Myers-Turnbull, T. Liu, B. Yaghoobi, L. J. Laskowski, E. I. Anderson, G. Zhang, J. Viswanathan, B. M. Brown, M. Tija, L. E. Dunlap, Z. T. Rabow, O. Fiehn, H. Wulff, J. D. McCorvy, P. J. Lein, D. Kokel, D. Ron, J. Peters, Y. Zuo, and D. E. Olson. 2021. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589(7842):474–479. https://doi.org/10.1038/s41586-020-3008-z.

Carhart-Harris, R. L., M. Bolstridge, J. Rucker, C. M. J. Day, D. Erritzoe, M. Kaelen, M. Bloomfield, J. A. Rickard, B. Forbes, A. Feilding, D. Taylor, S. Pilling, V. Curran, and D. J. Nutt. 2016. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry 3(7):619–627. https://doi.org/10.1016/S2215-0366(16)30065-7.

Carhart-Harris, R. L., L. Roseman, E. Haijen, D. Erritzoe, R. Watts, I. Branchi, and M. Kaelen. 2018. Psychedelics and the essential importance of context. Journal of Psychopharmacology 32(7):725–731. https://doi.org/10.1177/0269881118754710.

Carhart-Harris, R., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, J. Martell, A. Blemings, D. Erritzoe, and D. J. Nutt. 2021. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 384(15):1402–1411. https://doi.org/10.1056/NEJMoa2032994.

Colloca, L., and A. J. Barsky. 2020. Placebo and nocebo effects. New England Journal of Medicine 382(6):554–561. https://doi.org/10.1056/NEJMra1907805.

Colloca, L., and F. G. Miller. 2011. How placebo responses are formed: A learning perspective. Philosophical Transactions of the Royal Society B: Biological Sciences 366(1572):1859–1869. https://doi.org/10.1098/rstb.2010.0398.

Corkery J. M. 2018. Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers. Progress in Brain Research 242:217–257. https://doi.org/10.1016/bs.pbr.2018.08.005.

De Gregorio, D., A. Aguilar-Valles, K. H. Preller, B. D. Heifets, M. Hibicke, J. Mitchell, and G. Gobbi. 2021a. Hallucinogens in mental health: Preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. Journal of Neuroscience 41(5):891–900.

De Gregorio, D., J. Popic, J. P. Enns, A. Inserra, A. Skalecka, A. Markopoulos, L. Posa, M. Lopez-Canul, H. Qianzi, C. K. Lafferty, J. P. Britt, S. Comai, A. Aguilar-Valles, N. Sonenberg, and G. Gobbi. 2021b. Lysergic acid diethylamide (LSD) promotes social behavior through MTORC1 in the excitatory neurotransmission. Proceedings of the National Academy of Sciences of the United States of America 118(5):e2020705118. https://doi.org/10.1073/pnas.2020705118.

De Gregorio, D., A. Inserra, J. P. Enns, A. Markopoulos, M. Pileggi, Y. El Rahimy, M. Lopez-Canul, S. Comai, and G. Gobbi. 2022. Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. Neuropsychopharmacology 47(6):1188–1198. https://doi.org/10.1038/s41386-022-01301-9.

Dolder, P. C., Y. Schmid, F. Müller, S. Borgwardt, and M. E. Liechti. 2016. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 41(11):2638–2646. https://doi.org/10.1038/npp.2016.82.

Droogmans, S., B. Cosyns, H. D’haenen, E. Creeten, C. Weytjens, P. R. Franken, B. Scott, D. Schoors, A. Kemdem, L. Close, and J. L. Vandenbossche. 2007. Possible association between 3, 4-methylenedioxymethamphetamine abuse and valvular heart disease. The American Journal of Cardiology 100(9):1442–1445.

FDA (Food and Drug Administration). 2003. Guidance for industry: Exposure–response relationship—study design, data analysis, and regulatory applications. Department of Health and Human Services. https://www.fda.gov/media/71277/download.

Gasser, P., K. Kirchner, and T. Passie. 2015. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. Journal of Psychopharmacology 29(1):57–68. https://doi.org/10.1177/0269881114555249.

GBD (Global Burden of Disease) 2019 Mental Disorders Collaborators. 2022. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: A systematic analysis for the global burden of disease study 2019. The Lancet Psychiatry 9(2):137–150. https://doi.org/10.1016/S2215-0366(21)00395-3.

Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 30(12):1181–1197. https://doi.org/10.1177/0269881116675513.

Grinspoon, L., and J. B. Bakalar. 1979. Psychedelic drugs reconsidered. Vol. 168. New York: Basic Books.

Grob, C. S., R. E. Poland, L. Chang, and T. Ernst. 1996. Psychobiologic effects of 3,4 -methylenedioxymethamphetamine in humans: Methodological considerations and preliminary observations. Behavioural Brain Research 73(1–2):103–107. https://doi.org/10.1016/0166-4328(96)00078-2.

Gukasyan, N., A. K. Davis, F. S. Barrett, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, and R. R. Griffiths. 2022. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology 36(2):151–158. https://doi.org/10.1177/02698811211073759.

Hayes, S. C., K. D. Strosahl, and K. G. Wilson. 1999. Acceptance and commitment therapy an experiential approach to behavior change. New York: Guilford Press.

Holmes, S. E., S. J. Finnema, M. Naganawa, N. DellaGioia, D. Holden, K. Fowles, M. Davis, J. Ropchan, P. Emory, Y. Ye, N. Nabulsi, D. Matuskey, G. A. Angarita, R. H. Pietrzak, R. S. Duman, G. Sanacora, J. H. Krystal, R. E. Carson, and I. Esterlis. 2022. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry 27(4):2273–2281. https://doi.org/10.1038/s41380-022-01465-2.

Inserra, A., D. De Gregorio, T. Rezai, M. G. Lopez-Canul, S. Comai, and G. Gobbi. 2021. Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice. Journal of Psychopharmacology 35(4):469–482. https://doi.org/10.1177/0269881121991569.

Jerome, L., A. A. Feduccia, J. B. Wang, S. Hamilton, B. Yazar-Klosinski, A. Emerson, M. C. Mithoefer, and R. Doblin. 2020. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology 237(8):2485–2497. https://doi.org/10.1007/s00213-020-05548-2.

Johnson, M. W., A. Garcia-Romeu, and R. R. Griffiths. 2017. Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse 43(1):55–60. https://doi.org/10.3109/00952990.2016.1170135.

Johnson, M. W., R. R. Griffiths, P. S. Hendricks, and J. E. Henningfield. 2018. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142:143–166. https://doi.org/10.1016/j.neuropharm.2018.05.012.

Kettner, H., F. E. Rosas, C. Timmermann, L. Kärtner, R. L. Carhart-Harris, and L. Roseman. 2021. Psychedelic communitas: Intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness. Frontiers in Pharmacology 12. https://www.frontiersin.org/article/10.3389/fphar.2021.623985.

Kyzar, E. J., C. D. Nichols, R. R. Gainetdinov, D. E. Nichols, and A. V. Kalueff. 2017. Psychedelic drugs in biomedicine. Trends in Pharmacological Sciences 38(11):992–1005. https://doi.org/10.1016/j.tips.2017.08.003.

Levine, S. 2021. Ketamine: A cautionary tale. Psychology Today. https://www.psychologytoday.com/us/blog/pathways-progress/202111/ketamine-cautionary-tale.

Ly, C., A. C. Greb, L. P. Cameron, J. M. Wong, E. V. Barragan, P. C. Wilson, K. F. Burbach, S. Soltanzadeh, S. S. Zarandi, A. Sood, M. R. Paddy, and W. C. Duim. 2018. Psychedelics promote structural and functional neural plasticity. Cell Reports 23(11):3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022.

Markopoulos, A., A. Inserra, D. De Gregorio, and G. Gobbi. 2021. Evaluating the potential use of serotonergic psychedelics in autism spectrum disorder. Frontiers in Pharmacology 12.

McCulloch, D. E.-Wen, M. K. Madsen, D. S. Stenbæk, S. Kristiansen, B. Ozenne, P. S. Jensen, G. M. Knudsen, and P. M. Fisher. 2022. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. Journal of Psychopharmacology 36(1):74–84. https://doi.org/10.1177/02698811211026454.

Mitchell, J. M., M. Bogenschutz, A. Lilienstein, C. Harrison, S. Kleiman, K. Parker-Guilbert, M. Ot’alora G, W. Garas, C. Paleos, I. Garman, C. Nicholas, M. Mithoefer, S. Carlin, B. Poulter, A. Mithoefer, S. Quevedo, G. Wells, S. S. Klaire, B. van der Kolk, K. Tzarfaty, R. Amiaz, R. Worthy, S. Shannon, J. D. Woolley, C. Marta, Y. Gelfand, E. Hapke, S. Amar, Y. Wallach, R. Brown, S. Hamilton, J. B. Wang, A. Coker, R. Matthews, A. de Boer, B. Yazar-Klosinski, A. Emerson, and R. Doblin. 2021. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine 27(6):1025–1033. https://doi.org/10.1038/s41591-021-01336-3.

Mithoefer, M. C., A. A. Feduccia, L. Jerome, A. Mithoefer, M. Wagner, Z. Walsh, S. Hamilton, B. Yazar-Klosinski, A. Emerson, and R. Doblin. 2019. MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology 236(9):2735–2745. https://doi.org/10.1007/s00213-019-05249-5.

Nichols, D. E. 2022. Entactogens: How the name for a novel class of psychoactive agents originated. Frontiers in Psychiatry 13. https://www.frontiersin.org/article/10.3389/fpsyt.2022.863088.

Pahnke, W. N., and W. A. Richards. 1966. Implications of LSD and experimental mysticism. Journal of Religion and Health 5(3):175–208. https://doi.org/10.1007/BF01532646.

Petranker, R., T. Anderson, and N. Farb. 2020. Psychedelic research and the need for transparency: Polishing Alice’s looking glass. Frontiers in Psychology 11:1681. https://doi.org/10.3389/fpsyg.2020.01681.

Preller, K. H., A. Razi, P. Zeidman, P. Stämpfli, K. J. Friston, and F. X. Vollenweider. 2019. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proceedings of the National Academy of Sciences of the United States of America 116(7):2743–2748. https://doi.org/10.1073/pnas.1815129116.

Reiff, C. M., E. E. Richman, C. B. Nemeroff, L. L. Carpenter, A. S. Widge, C. I. Rodriguez, N. H. Kalin, W. M. McDonald, and the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. 2020. Psychedelics and psychedelic-assisted psychotherapy. American Journal of Psychiatry 177(5):391–410. https://doi.org/10.1176/appi.ajp.2019.19010035.

Roseman, L., D. J. Nutt, and R. L. Carhart-Harris. 2018. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology 8. https://www.frontiersin.org/article/10.3389/fphar.2017.00974.

Roseman, L., E. Haijen, K. Idialu-Ikato, M. Kaelen, R. Watts, and R. Carhart-Harris. 2019. Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. Journal of Psychopharmacology 33(9):1076–1087. https://doi.org/10.1177/0269881119855974.

Ross, S., A. Bossis, J. Guss, G. Agin-Liebes, T. Malone, B. Cohen, S. E. Mennenga, A. Besler, K. Kalliontzi, J. Babb, Z. Su, P. Corby, and B. Schmidt. 2016. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology 30(12):1165–1180. https://doi.org/10.1177/0269881116675512.

Rucker, J. J., L. Marwood, R.-L. J. Ajantaival, C. Bird, H. Eriksson, J. Harrison, M. Lennard-Jones, S. Mistry, F. Saldarini, S. Stansfield, S. J. Tai, S. Williams, N. Weston, E. Malievskaia, and A. H. Young. 2022. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. Journal of Psychopharmacology 36(1):114–125. https://doi.org/10.1177/02698811211064720.

Schulenberg, J. E., M. E. Patrick, L. D. Johnston, P. M. O’Malley, J. G. Bachman, and R. A. Miech. 2021. Monitoring the Future national survey results on drug use, 1975–2020: Volume II, College students and adults ages 19–60. Ann Arbor, MI: Institute for Social Research, University of Michigan. http://monitoringthefuture.org/pubs.html#monographs.

Sellers, E. M., M. K. Romach, and D. B. Leiderman. 2018. Studies with psychedelic drugs in human volunteers. Neuropharmacology 142(November):116–134. https://doi.org/10.1016/j.neuropharm.2017.11.029.

Shao, L.-X., C. Liao, I. Gregg, P. A. Davoudian, N. K. Savalia, K. Delagarza, and A. C. Kwan. 2021. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109(16):2535–2544. https://doi.org/10.1016/j.neuron.2021.06.008.

Vollenweider, F. X. 2001. Brain mechanisms of hallucinogens and entactogens. Dialogues in Clinical Neuroscience 3(4):265–279.

Vollenweider, F. X., and M. Kometer. 2010. The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Reviews Neuroscience 11(9):642–651. https://doi.org/10.1038/nrn2884.

Vollenweider, F. X., and K. H. Preller. 2020. Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience 21(11):611–624. https://doi.org/10.1038/s41583-020-0367-2.

Wasson, R. G. 1957. Seeking the magic mushroom. Life, May 13, 1957.

Watts, R., and J. B. Luoma. 2020. The use of the psychological flexibility model to support psychedelic assisted therapy. Journal of Contextual Behavioral Science 15(January):92–102. https://doi.org/10.1016/j.jcbs.2019.12.004.

Zittoun, T., and S. Brinkmann. 2012. Learning as meaning making. In N. M. Seel (ed.), Encyclopedia of the sciences of learning. Boston, MA: Springer. https://doi.org/10.1007/978-1-4419-1428-6_1851.

This page intentionally left blank.